Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28119069 | 0.97 | PTPN1 (0.48) | PTPN1MAOBMAOAPTPN2POLB | |
| SCHEMBL27697038 | 0.87 | PTPN1 (0.43) | PTPN1MAOBMAOAPTPN2POLB | |
| SCHEMBL16619452 | 0.78 | PON1 (0.41) | EPHX2PIM1PIM2KDM4E | |
| SCHEMBL4989809 | 0.77 | PTPN1 (0.78) | PTPN1MAOBMAOAPTPN2POLB | |
| SCHEMBL4446704 | 0.74 | KIF11 (0.42) | MAOBEPHX2PIM1PIM2KDM4E | |
| SCHEMBL15898959 | 0.74 | PTPN1 (0.78) | PTPN1MAOBMAOAPTPN2POLB | |
| SCHEMBL15951253 | 0.74 | PTPN1 (0.78) | PTPN1MAOBMAOAPTPN2POLB | |
| SCHEMBL20274083 | 0.74 | EPHX2 (0.41) | MAOBMAOAEPHX2PIM1PIM2 | |
| SCHEMBL21116465 | 0.73 | TP53 (0.46) | MAOBMAOAEPHX2 | |
| SCHEMBL29955641 | 0.73 | PTPN1 (0.61) | PTPN1MAOBMAOAPTPN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126361-B1 | CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3126361-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015150957-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | PFIZER (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | CYP4B1, CTRB1, CTRB2 | PTPN1 1442/4885MAOB 55/4885MAOA 121/4885 |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PRNP, MAOB | PTPN1 1304/4885MAOB 3/4885MAOA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.